目的 分析2014-2016年綿陽市中心醫(yī)院女性泌尿生殖道感染的病原菌分布及耐藥性。方法 選取2014年1月-2016年1月在綿陽市中心醫(yī)院接受治療的泌尿生殖道感染的女性患者180例，對患者宮頸分泌物進(jìn)行病原菌培養(yǎng)和藥敏試驗(yàn)，根據(jù)醫(yī)用物品使用說明書觀察病原菌的分布，并分析其耐藥性。結(jié)果 180例患者中共分離出病原菌410株，支原體有288株（70.24%），其中解脲脲支原體以133株（32.43%）居首，其次為人型支原體59株（14.39%）；細(xì)菌有122株（29.76%），其中腸桿菌以48株（11.71%）居首，其次為表皮葡萄球菌35株（8.54%）。支原體中解脲脲支原體和人型支原體以及細(xì)菌中腸桿菌和表皮葡萄球菌對紅霉素、氧氟沙星、環(huán)丙沙星和四環(huán)素的耐藥性較高，均>70%；對原始霉素、強(qiáng)力霉素、交沙霉素和米諾環(huán)素的耐藥性較低，均<10%。結(jié)論 女性泌尿生殖道感染的病原菌以支原體為主、細(xì)菌為輔，且二者對原始霉素、強(qiáng)力霉素、交沙霉素和米諾環(huán)素等藥物的耐藥性均較低，因此治療女性泌尿生殖道感染疾病應(yīng)采用原始霉素等藥物以抑制支原體為主，并輔以細(xì)菌抑制。

Objective To analyze the distribution and drug resistance of female urinary tract infection of Mianyang Central Hospital during 2014-2016. Methods Female patient (180 cases) with urinary tract infection were selected from January 2014 to 2016 January in Mianyang Central Hospital. The primary culture and drug sensitivity test were performed in the patients with cervical secretion, the distribution of the pathogen was observed, and their resistance was analyzed according to medical goods instructions. Results A total of 410 strains of pathogens were isolated. There were 288 strains of mycoplasma (70.24%). Among them, there were 133 strains of Ureaplasma urealyticum, accounted for 32.43%, ranked first. Then followed by 59 strains of human mycoplasma (14.39%). There were 122 strains of bacteria (29.76%), including Escherichia coli (48 strains, 11.71%) and Staphylococcus epidermidis (35 strains, 8.54%). Four types of mycoplasmas had relatively higher resistance to erythromycin, ofloxacin, ciprofloxacin, and tetracycline with resistant rates above 70%, but lower resistance to pristinamycin, doxycycline, josamycin, and minocycline with resistant rates below 10%. Conclusion The pathogen of female urinary tract infection are mainly caused by mycoplasma, and bacteria as a supplement. And their resistance to pristinamycin, doxycycline, josamycin, minocycline, and other drugs are relatively low, so treatment of female urinary tract infections should be treated with primary mold and other drugs to inhibit the main mycoplasma, supplemented by bacterial inhibition.